These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 37151295)

  • 1. Illuminating the druggable genome through patent bioactivity data.
    Magariños MP; Gaulton A; Félix E; Kiziloren T; Arcila R; Oprea TI; Leach AR
    PeerJ; 2023; 11():e15153. PubMed ID: 37151295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of the Core Chemical Structure in SureChEMBL Patents.
    Falaguera MJ; Mestres J
    J Chem Inf Model; 2021 May; 61(5):2241-2247. PubMed ID: 33929850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods.
    Zdrazil B; Felix E; Hunter F; Manners EJ; Blackshaw J; Corbett S; de Veij M; Ioannidis H; Lopez DM; Mosquera JF; Magarinos MP; Bosc N; Arcila R; Kizilören T; Gaulton A; Bento AP; Adasme MF; Monecke P; Landrum GA; Leach AR
    Nucleic Acids Res; 2024 Jan; 52(D1):D1180-D1192. PubMed ID: 37933841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SureChEMBL: a large-scale, chemically annotated patent document database.
    Papadatos G; Davies M; Dedman N; Chambers J; Gaulton A; Siddle J; Koks R; Irvine SA; Pettersson J; Goncharoff N; Hersey A; Overington JP
    Nucleic Acids Res; 2016 Jan; 44(D1):D1220-8. PubMed ID: 26582922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the significance of patent-derived information for the early identification of compound-target interaction hypotheses.
    Senger S
    J Cheminform; 2017 Apr; 9(1):26. PubMed ID: 29086108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ChEMBL: a large-scale bioactivity database for drug discovery.
    Gaulton A; Bellis LJ; Bento AP; Chambers J; Davies M; Hersey A; Light Y; McGlinchey S; Michalovich D; Al-Lazikani B; Overington JP
    Nucleic Acids Res; 2012 Jan; 40(Database issue):D1100-7. PubMed ID: 21948594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ChEMBL database in 2017.
    Gaulton A; Hersey A; Nowotka M; Bento AP; Chambers J; Mendez D; Mutowo P; Atkinson F; Bellis LJ; Cibrián-Uhalte E; Davies M; Dedman N; Karlsson A; Magariños MP; Overington JP; Papadatos G; Smit I; Leach AR
    Nucleic Acids Res; 2017 Jan; 45(D1):D945-D954. PubMed ID: 27899562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrieving GPCR data from public databases.
    Southan C
    Curr Opin Pharmacol; 2016 Oct; 30():38-43. PubMed ID: 27472010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing expectations: assessment of chemistry databases generated by automated extraction of chemical structures from patents.
    Senger S; Bartek L; Papadatos G; Gaulton A
    J Cheminform; 2015 Dec; 7(1):49. PubMed ID: 26457120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Making every SAR point count: the development of Chemistry Connect for the large-scale integration of structure and bioactivity data.
    Muresan S; Petrov P; Southan C; Kjellberg MJ; Kogej T; Tyrchan C; Varkonyi P; Xie PH
    Drug Discov Today; 2011 Dec; 16(23-24):1019-30. PubMed ID: 22024215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parallel worlds of public and commercial bioactive chemistry data.
    Lipinski CA; Litterman NK; Southan C; Williams AJ; Clark AM; Ekins S
    J Med Chem; 2015 Mar; 58(5):2068-76. PubMed ID: 25415348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug target ontology to classify and integrate drug discovery data.
    Lin Y; Mehta S; Küçük-McGinty H; Turner JP; Vidovic D; Forlin M; Koleti A; Nguyen DT; Jensen LJ; Guha R; Mathias SL; Ursu O; Stathias V; Duan J; Nabizadeh N; Chung C; Mader C; Visser U; Yang JJ; Bologa CG; Oprea TI; Schürer SC
    J Biomed Semantics; 2017 Nov; 8(1):50. PubMed ID: 29122012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innovation in Small-Molecule-Druggable Chemical Space: Where are the Initial Modulators of New Targets Published?
    Ashenden SK; Kogej T; Engkvist O; Bender A
    J Chem Inf Model; 2017 Nov; 57(11):2741-2753. PubMed ID: 29068231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A drug target slim: using gene ontology and gene ontology annotations to navigate protein-ligand target space in ChEMBL.
    Mutowo P; Bento AP; Dedman N; Gaulton A; Hersey A; Lomax J; Overington JP
    J Biomed Semantics; 2016 Sep; 7(1):59. PubMed ID: 27678076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opening up connectivity between documents, structures and bioactivity.
    Southan C
    Beilstein J Org Chem; 2020; 16():596-606. PubMed ID: 32280387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PEMT: a patent enrichment tool for drug discovery.
    Gadiya Y; Zaliani A; Gribbon P; Hofmann-Apitius M
    Bioinformatics; 2023 Jan; 39(1):. PubMed ID: 36322820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring SureChEMBL from a drug discovery perspective.
    Gadiya Y; Shetty S; Hofmann-Apitius M; Gribbon P; Zaliani A
    Sci Data; 2024 May; 11(1):507. PubMed ID: 38755219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanding opportunities for mining bioactive chemistry from patents.
    Southan C
    Drug Discov Today Technol; 2015 Jul; 14():3-9. PubMed ID: 26194581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating error rates in bioactivity databases.
    Tiikkainen P; Bellis L; Light Y; Franke L
    J Chem Inf Model; 2013 Oct; 53(10):2499-505. PubMed ID: 24160896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CIPSI: An open chemical intellectual property service for medicinal chemists.
    Martinez-Sevillano M; Falaguera MJ; Mestres J
    Mol Inform; 2024 Jan; 43(1):e202300221. PubMed ID: 38010631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.